Log in with your email address username.


[Correspondence] PATHWAY-2: spironolactone for resistant hypertension

We read with great interest the study by Bryan Williams and colleagues (Nov 21, p 2059),1 which confirmed for the first time the superiority of spironolactone over α blockers and β blockers in resistant hypertension—a very important clinical finding. We would like to draw attention to some aspects.